IN SHORT
IV stem cell therapy means giving cells, usually mesenchymal stromal cells, through a drip into a vein. In the US only one such product is FDA-approved, for a rare complication in children after a bone marrow transplant; IV infusions sold for anti-ageing, pain or chronic disease are unapproved.
What is iv stem cell therapy?
An IV (intravenous) stem cell treatment puts living cells straight into the bloodstream. Most clinics say they use mesenchymal stromal cells (MSCs) from umbilical cord tissue, fat or bone marrow. Some products sold as ‘stem cells’ contain few or no living cells. The term covers very different products, so the label alone tells you little.
How it works
Cells are either taken from your own body or from a donor tissue such as an umbilical cord. Donor cells are usually grown in a lab, frozen, then thawed and diluted in saline. The infusion typically takes 30 to 90 minutes through a cannula in the arm. Research suggests most infused MSCs get trapped in the lungs and are cleared within days, so any effect is thought to come from signals they release rather than from cells ‘repairing’ distant organs.
Legal status
In the US, cells grown in a lab or used for a different job than in the body are regulated as drugs (Section 351) and need FDA approval; they do not qualify for the lighter Section 361 tissue rules. In December 2024 the FDA approved the first MSC therapy, an IV product for children with steroid-refractory acute graft-versus-host disease; no IV stem cell product is approved for ageing, joints, autism, lung, heart or brain disease.
In the EU, such cells are ‘advanced therapy medicinal products’ that need marketing authorisation, and the European Medicines Agency warned against unproven cell therapies in 2020. Japan has a separate conditional-approval pathway, but clinics abroad offering IV infusions often operate outside formal trials.
What the evidence shows
The strongest human evidence is in steroid-refractory acute graft-versus-host disease in children, which led to the 2024 FDA approval. For lung injury (ARDS), including COVID-19, meta-analyses of small trials show possible benefit, but results are mixed and not practice-changing. Trials in stroke, heart failure, multiple sclerosis and frailty have been mostly small and early-phase, with no therapy proven to work.
Safety reviews of randomised trials, including a 2026 review of 42 umbilical cord MSC trials (2,280 patients), found the main consistent side effect was fever, without clear signals for cancer or clots in trial settings. Trial safety does not transfer to commercial clinics, where product quality and dosing are not checked.
Commonly marketed for
- Anti-ageing and ‘longevity’ infusions
- Chronic fatigue and post-viral symptoms
- Autoimmune conditions such as lupus or rheumatoid arthritis
- Neurological conditions such as Parkinson’s, MS or stroke recovery
- Lung disease such as COPD
- General joint and back pain
Cost
No peer-reviewed price survey for IV stem cell infusions was found. A 2017 study of 317 US clinics found stem cell knee injections averaged $5,156 (range $1,150 to $12,000); IV infusions and multi-dose packages are typically marketed at or above this level, and insurance does not cover unapproved use.
Risks
- Fever, chills and infusion reactions
- Serious infections from contaminated products, as documented by the CDC in 2018
- Blood clots or blockage in the lungs, a concern raised for some cell types
- Unknown long-term effects, including theoretical risk of abnormal tissue growth
- Paying large sums for an unproven product and delaying effective care
Questions to ask first
- Is this product FDA-approved for my condition, or am I in a registered clinical trial with FDA oversight (an IND number)?
- Where do the cells come from, how are they tested, and how many living cells are in each dose?
- What published, peer-reviewed evidence supports this infusion for my specific condition?
- Who handles complications, and what emergency care is available if I react badly?
Before You Pay: The Stem Cell Clinic Checklist
- 20 questions every legitimate clinic should answer in writing
- A red-flag scorecard to spot unregulated marketing
- Realistic 2026 cost ranges: US, Mexico, Panama & Europe
- How to find a registered clinical trial
IV Stem Cell Therapy: FAQs
Is IV stem cell therapy FDA-approved?
Only one IV mesenchymal stromal cell product is FDA-approved, since December 2024, for children with steroid-refractory acute graft-versus-host disease. Cord blood-forming stem cells are also approved for blood disorders. IV infusions sold for ageing, pain or chronic disease are not approved.
Where do the infused cells go?
Studies suggest most IV-infused MSCs lodge in the lungs first and are cleared within days. This is why claims that cells travel to and rebuild a damaged knee, brain or heart are not supported.
Is IV stem cell therapy safe?
In controlled trials, fever is the most consistent side effect, and serious problems have been uncommon. Outside trials, the FDA and CDC have documented infections and other serious harms linked to unapproved products.
Does insurance pay for IV stem cells?
Insurers generally do not pay for unapproved stem cell infusions. You would usually pay the full cost yourself.
Can I get IV stem cells legally in a trial?
Yes. Many legitimate trials are listed on ClinicalTrials.gov, and genuine trials usually do not charge participants. A listing alone does not prove a study is legitimate, so check for regulator oversight.
Related guides
- Mesenchymal Stem Cells (MSCs)
- Umbilical Cord Stem Cells
- Placental & Amniotic Stem Cell Products
- Exosome Therapy
- PRP vs Stem Cells
- All treatment types · Glossary
Sources
- FDA: FDA approves first mesenchymal stromal cell therapy to treat steroid-refractory acute GVHD (Dec 2024)
- FDA: Important patient and consumer information about regenerative medicine therapies
- Safety of intravascular administration of umbilical-cord-derived MSCs: updated systematic review and meta-analysis (Stem Cells Transl Med, 2026)
- Cell therapy with intravascular administration of MSCs continues to appear safe: updated systematic review (eClinicalMedicine)
- Efficacy and safety of MSCs and extracellular vesicles for ARDS: systematic review and meta-analysis
- CDC: Stem cell and exosome products (infection investigations)
- EMA warns against using unproven cell-based therapies (2020)
- Stem cell centers on the rise, claim high efficacy for knee osteoarthritis (AAOS, cost survey)
Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.